DURECT Corporation Receives FDA Breakthrough Therapy Designation For Larsucosterol In Alcohol-Associated Hepatitis
DURECT Corporation Receives FDA Breakthrough Therapy Designation For Larsucosterol In Alcohol-Associated Hepatitis
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.